The Federal Register

Pacific Proving Grounds

Thu, May 5 2005 11:00:00 GMT

The Department of Health and Human Services gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees at the Pacific Proving Grounds, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

Facility: Pacific Proving Grounds, Marshall Islands.

Locations: Enewetak Atoll.

Job Titles and/or Job Duties: All scientists and scientific couriers.

Period of Employment: July 1, 1958, until August 31, 1958 (Operation Hardtack I).

Food Labeling: Safe Handling Statements: Labeling of Shell Eggs

Thu, May 5 2005 11:00:00 GMT

The Food and Drug Administration (FDA) is proposing to amend the agency's food labeling regulations to permit the egg industry to place the safe handling statement for shell eggs on the inside lid of egg cartons if the statement ``Keep Refrigerated'' appears on the principal display panel (PDP) or information panel. This proposed rule, if finalized, will provide the industry greater flexibility in the placement of safe handling instructions on egg cartons, while continuing to provide consumers with this important information. This proposed action is in response to numerous requests from the egg industry.

National Toxicology Program; Office of Chemical Nomination and Selection; Announcement of and Request for Public

Thu, May 5 2005 11:00:00 GMT

The National Toxicology Program (NTP) continuously solicits and accepts nominations for toxicological studies to be undertaken by the program. Nominations of substances of potential human health concern are received from federal agencies, the public and other interested parties. These nominations are subject to several levels of review before selections for testing are made and toxicological studies are designed and implemented. This notice (1) provides brief background information and study recommendations regarding 15 nominations for NTP study (Table 1), (2) solicits public comment on the nominations and study recommendations, and (3) requests the submission of additional relevant information for consideration by the NTP in its continued evaluation of these nominations. An electronic copy of this announcement, Internet links to electronic versions of supporting documents for each nomination, and further information on the NTP and the NTP Study Nomination and Review Process can be accessed thr

Prospective Grant of Exclusive License: Use of Human Papilloma Virus (HPV) Immunoreactive Peptides for the

Thu, May 5 2005 11:00:00 GMT

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in:

PCT/US02/09261 filed March 22, 2002, entitled ``Human Papilloma Virus Immunoreactive Peptides'' (E1262001/0PCT02), (Inventors: Samir N. Khleif and Jay Berzofsky) (NCI), prior U.S. provisional application 60/278,520, filed March 23, 2001, now abandoned. National stage filed March 22, 2002: In U.S. Patent Application No. 10/472,661; in Canada Patent Application No. 2,441,947; in EPO Patent Application No. 02728570.9; in Australia Patent Application No. 2002258614 to Panacea Biotec Ltd. (hereafter PBL), having a place of business in New Deli, India. The patent rights in these inventions have been assigned to the United States of America.

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Thu, May 5 2005 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provision set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel Review of Research Project Applications (R01s).

Date: June 23, 2005.

Time: 6:30 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: The Watergate, 2650 Virginia Avenue, NW., Washington, DC 20037.

Contact Person: Irina Gordienko, PhD, Review Branch, NIH, NHLB

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Thu, May 5 2005 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Heart, Lung, and Blood Initial Review Group, Heart, Lung, and Blood Program Project Review Committee.

Date: June 15, 2005.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Jeffrey H. Hurst, PhD, Review Branch, Division of Ex

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Thu, May 5 2005 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel ``NIH AIDS Research and Reference Reagent Program''.

Date: May 13, 2005.

Time: 11 a.m. to 2 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Cal

National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

Thu, May 5 2005 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 0571, Review of R01.

Date: May 18, 2005.

Time: 11 a.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Rebecca Ro

National Institute of Dental & Craniofacial Research; Notice of Closed Meeting

Thu, May 5 2005 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

Name of Committee: NIDCR Special Grants Review Committee 0573, Review of R03s, Fs, Ks.

Date: June 1617, 2005.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda, MD, Marriott Bethesda North Hotel and Conference Ctr, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Lynn Mertens King, PhD, Scientific Review Administ

National Institute of General Medical Sciences; Amended Notice of Meeting

Thu, May 5 2005 11:00:00 GMT

Notice is hereby given of a change in the meeting of the National Advisory General Medical Sciences Council, May 19, 2005, 8:30 a.m. to May 20, 2005, 5 p.m. National Institutes of Health, Natcher Building, Conference Rooms E1 and E2, 9000 Rockville Pike, Bethesda, MD 20892 which was published in the Federal Register on April 20, 2005, 70 FR 2058220583.

On May 19, 2005, the meeting will be closed from 8:30 a.m. to 3 p.m. and open from 3 p.m. to 5:30 p.m. On May 20, 2005, the meeting will be closed from 8:30 a.m. to 12 p.m. The meeting is partially closed to the public.

Dated: April 27, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 058962 Filed 5405; 8:45 am]
BILLING CODE 414001M

Prospective Grant of an Exclusive License: Cancer Diagnostic Based on Detecting Expression of Human Brother of

Thu, May 5 2005 11:00:00 GMT

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), announces that the Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Provisional Patent Application Serial No. 60/611,789, entitled ``Method of Detecting Cancer Based On Immune Reaction To BORIS'' filed September 21, 2004 (E2412004/0US01); U.S. Provisional Patent Application Serial No. 60/358,889, entitled ``Brother of The Regulator of Imprinted Sites (BORIS)'' filed February 22, 2001 (E2272001/0US01); PCT Application No. PCT/US03/05186, entitled ``Brother of The Regulator of Imprinted Sites (BORIS)'' filed February 21, 2003 (E2272001/0PCT02); and U.S. Patent Application Serial No. 10/505,377, entitled ``Brother of The Regulator of Imprinted Sites (BORIS)'' filed August 19, 2004 (E2272001/0US03), to NewLink Genetics Corporation, having a place of business in Ames, Iowa.

The prospective exclusive territory may be United States